

# Boe Sandahl Sorensen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6928033/boe-sandahl-sorensen-publications-by-citations.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88 papers	2,304 citations	25 h-index	45 g-index
92 ext. papers	2,683 ext. citations	4.5 avg, IF	4.92 L-index

#	Paper	IF	Citations
88	Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma. <i>Journal of Extracellular Vesicles</i> , <b>2015</b> , 4, 26659	16.4	189
87	Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1708-10	11.4	154
86	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. <i>Cancer</i> , <b>2014</b> , 120, 3896-901	6.4	151
85	Positron emission tomography (PET) imaging with [ <sup>11</sup> C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. <i>Cancer Research</i> , <b>2009</b> , 69, 873-8	10.1	135
84	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. <i>BMC Cancer</i> , <b>2014</b> , 14, 294	4.8	116
83	Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 114, 263-75	4.4	111
82	Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1287-9	8.9	98
81	Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). <i>Biochemical Pharmacology</i> , <b>1993</b> , 46, 389-93	6	75
80	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. <i>Lung Cancer</i> , <b>2016</b> , 100, 77-84	5.9	70
79	Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 798-804	2.2	68
78	Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. <i>Biochemical Pharmacology</i> , <b>1993</b> , 45, 2025-35	6	59
77	Estrogen receptor $\beta$ is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 139, 71-80	4.4	55
76	The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2016</b> , 5, 172-82	4.4	53
75	Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing. <i>Translational Oncology</i> , <b>2018</b> , 11, 1220-1224	4.9	44
74	Expression of the epidermal growth factor system in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , <b>2007</b> , 104, 158-67	4.9	40
73	ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. <i>Prostate</i> , <b>2003</b> , 56, 142-9	4.2	34
72	EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer. <i>Lung Cancer</i> , <b>2014</b> , 83, 224-30	5.9	33

71	Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 704-709	8.7	31
70	Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. <i>Melanoma Research</i> , <b>2005</b> , 15, 409-416	3.3	29
69	Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4. <i>PLoS ONE</i> , <b>2014</b> , 9, e94606	3.7	28
68	Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. <i>Lung Cancer</i> , <b>2016</b> , 94, 81-7	5.9	28
67	Day-to-day and within-day biological variation of cell-free DNA. <i>EBioMedicine</i> , <b>2019</b> , 49, 284-290	8.8	27
66	The influence of immunohistochemistry on mRNA recovery from microdissected frozen and formalin-fixed, paraffin-embedded sections. <i>Diagnostic Molecular Pathology</i> , <b>2004</b> , 13, 224-33		26
65	Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and cultured cardiomyocytes. <i>PLoS ONE</i> , <b>2012</b> , 7, e40243	3.7	25
64	Mouse transcobalamin has features resembling both human transcobalamin and haptocorrin. <i>PLoS ONE</i> , <b>2011</b> , 6, e20638	3.7	25
63	Transcellular transport of vitamin B(12) in LLC-PK1 renal proximal tubule cells. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2001</b> , 12, 1099-1106	12.7	23
62	Pathologic assessment of melanoma sentinel nodes: a role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 1425-33	12.9	22
61	Increased PD-L1 expression in erlotinib-resistant NSCLC cells with gene amplification is reversed upon MET-TKI treatment. <i>Oncotarget</i> , <b>2017</b> , 8, 68221-68229	3.3	21
60	A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. <i>Acta Oncologica</i> , <b>2008</b> , 47, 618-32	3.2	21
59	Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. <i>Journal of Molecular Diagnostics</i> , <b>2018</b> , 20, 483-494	5.1	19
58	Insulin induces a transcriptional activation of epiregulin, HB-EGF and amphiregulin, by a PI3K-dependent mechanism: identification of a specific insulin-responsive promoter element. <i>Biochemical and Biophysical Research Communications</i> , <b>2007</b> , 354, 885-91	3.4	17
57	IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells. <i>Oncotarget</i> , <b>2017</b> , 8, 33300-33315	3.3	16
56	A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. <i>Oncotarget</i> , <b>2018</b> , 9, 31066-31076	3.3	16
55	Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system. <i>FEBS Journal</i> , <b>2006</b> , 273, 5479-89	5.7	15
54	Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition. <i>Prostate</i> , <b>2005</b> , 64, 1-8	4.2	15

53	Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer. <i>Anticancer Research</i> , <b>2010</b> , 30, 2463-8	2.3	15
52	Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. <i>Lung Cancer</i> , <b>2019</b> , 135, 92-96	5.9	14
51	Expression of the epidermal growth factor system in eutopic endometrium from women with endometriosis differs from that in endometrium from healthy women. <i>Gynecologic and Obstetric Investigation</i> , <b>2009</b> , 67, 118-26	2.5	14
50	TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , <b>2020</b> , 55, 1433-1440	2.4	14
49	Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 11542	4.9	13
48	HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma. <i>Melanoma Research</i> , <b>2014</b> , 24, 88-91	3.3	13
47	Quantitation of the mRNA expression of the epidermal growth factor system: selective induction of heparin-binding epidermal growth factor-like growth factor and amphiregulin expression by growth factor stimulation of prostate stromal cells. <i>Translational Research</i> , <b>2000</b> , 136, 209-17		13
46	Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib. <i>Lung Cancer</i> , <b>2015</b> , 90, 314-20	5.9	12
45	Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. <i>Tumor Biology</i> , <b>2017</b> , 39, 1010428317730976	2.9	12
44	The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. <i>BMC Cancer</i> , <b>2018</b> , 18, 191	4.8	11
43	EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib. <i>Lung Cancer</i> , <b>2014</b> , 85, 435-41	5.9	11
42	Transcobalamin deficiency caused by compound heterozygosity for two novel mutations in the TCN2 gene: a study of two affected siblings, their brother, and their parents. <i>Journal of Inherited Metabolic Disease</i> , <b>2010</b> , 33 Suppl 3, S269-74	5.4	11
41	A single rainbow trout cobalamin-binding protein stands in for three human binders. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 33917-25	5.4	11
40	Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy. <i>Stem Cells International</i> , <b>2016</b> , 2016, 9601493	5	11
39	Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. <i>Translational Oncology</i> , <b>2016</b> , 9, 505-511	4.9	11
38	Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC. <i>Translational Oncology</i> , <b>2019</b> , 12, 432-440	4.9	11
37	Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
36	Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases. <i>SpringerPlus</i> , <b>2013</b> , 2, 464		10

35	Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer. <i>BJU International</i> , <b>2015</b> , 115, 163-5	5.6	10
34	Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1946-9	8.9	10
33	The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. <i>Molecular and Cellular Biochemistry</i> , <b>2004</b> , 260, 129-35	4.2	10
32	Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. <i>Lung Cancer</i> , <b>2020</b> , 141, 37-43	5.9	10
31	Neurofilament Light Chain as A Biomarker for Brain Metastases. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
30	Intra-individual variation of circulating tumour DNA in lung cancer patients. <i>Molecular Oncology</i> , <b>2019</b> , 13, 2098-2106	7.9	9
29	The prognostic role of inflammation-scores on overall survival in lung cancer patients. <i>Acta Oncologica</i> , <b>2019</b> , 58, 371-376	3.2	9
28	EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 161-166.e1	4.9	8
27	Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. <i>Lung Cancer</i> , <b>2020</b> , 143, 67-72	5.9	8
26	Regulatory dissection of the CBX5 and hnRNPA1 bi-directional promoter in human breast cancer cells reveals novel transcript variants differentially associated with HP1 $\alpha$ down-regulation in metastatic cells. <i>BMC Cancer</i> , <b>2016</b> , 16, 32	4.8	8
25	Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma. <i>Journal of Investigative Dermatology</i> , <b>2006</b> , 126, 849-54	4.3	8
24	S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma. <i>Melanoma Research</i> , <b>2004</b> , 14, 211-5	3.3	8
23	Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. <i>Tumor Biology</i> , <b>2018</b> , 40, 1010428318811207	2.9	8
22	Gene Expression of the EGF System-a Prognostic Model in Non-Small Cell Lung Cancer Patients Without Activating EGFR Mutations. <i>Translational Oncology</i> , <b>2016</b> , 9, 306-12	4.9	7
21	Epidermal growth factor and insulin-like growth factor I upregulate the expression of the epidermal growth factor system in rat liver. <i>Journal of Hepatology</i> , <b>2000</b> , 32, 645-54	13.4	7
20	Expression of the epidermal growth factor system in human middle ear cholesteatoma. <i>Acta Oto-Laryngologica</i> , <b>2014</b> , 134, 124-34	1.6	6
19	Quantitative real-time RT-PCR in sentinel lymph nodes from melanoma patients. Detection of melanocytic mRNA predicts disease-free survival. <i>Apmis</i> , <b>2008</b> , 116, 199-205	3.4	6
18	The chemotherapeutic agent VP16 increases the stability of HB-EGF mRNA by a mechanism involving the 3SUTR. <i>Experimental Cell Research</i> , <b>2006</b> , 312, 3651-8	4.2	6

17	Simultaneous quantitation of several mRNA species by calibrated reverse transcription polymerase chain reaction and capillary electrophoresis: analysis of the epidermal growth factor receptor and its activating ligands EGF, TGF- $\alpha$ , and HB-EGF in rat liver. <i>Laboratory Investigation</i> , <b>2000</b> , 80, 983-6	5.9	6
16	The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor $\beta$ is not expressed. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2013</b> , 73, 503-13	2	5
15	Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis. <i>BJU International</i> , <b>2007</b> , 99, 196-201	5.6	5
14	Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients. <i>Lung Cancer</i> , <b>2020</b> , 147, 244-251	5.9	5
13	Soluble HER3 predicts survival in bladder cancer patients. <i>Oncology Letters</i> , <b>2018</b> , 15, 1783-1788	2.6	4
12	Identifying responders to trastuzumab therapy in breast cancer. <i>Future Oncology</i> , <b>2011</b> , 7, 767-73	3.6	4
11	Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
10	Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. <i>BMC Cancer</i> , <b>2021</b> , 21, 376	4.8	3
9	STAT3 is over-activated within CD163 bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	3
8	Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of -amplified EGFR-TKI resistant non-small cell lung cancer cells. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1904-1914	4.4	2
7	Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2016</b> , 76, 243-8	2	2
6	CELL-FREE DNA AND CLINICAL CHARACTERISTICS IN PATIENTS WITH SMALL INTESTINAL OR PANCREATIC NEUROENDOCRINE TUMORS. <i>Neuroendocrinology</i> , <b>2021</b> ,	5.6	2
5	Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC. <i>Case Reports in Oncology</i> , <b>2021</b> , 14, 1323-1327	1	2
4	cGAS-STING pathway expression as a prognostic tool in NSCLC. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 340-354	4.4	2
3	Calcium-induced apoptosis is delayed by HER1 receptor signalling through the Akt and PLC $\beta$ pathways in bladder cancer cells. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2011</b> , 71, 45-51	2	1
2	Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, e870-e877	4.9	1
1	EGFR transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation (cfChIP). <i>Molecular Oncology</i> , <b>2021</b> , 15, 2868-2876	7.9	0